Kiren Purushotorman
Overview
Explore the profile of Kiren Purushotorman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liao K, Eshaghi M, Hong Z, Saw T, Lim J, Han J, et al.
Nucleic Acids Res
. 2025 Mar;
53(4).
PMID: 40036878
Circular RNAs are an increasingly important class of RNA molecules that can be engineered as RNA vaccines and therapeutics. Here, we screened eight different group I introns for their ability...
2.
Quek A, Wang S, Teng O, Shunmuganathan B, Er B, Mahmud N, et al.
J Infect
. 2024 Aug;
89(4):106238.
PMID: 39121971
Background: Immunity to SARS-CoV-2 vaccination and infection differs considerably among individuals. We investigate the critical pathways that influence vaccine-induced cross-variant serological immunity among individuals at high-risk of COVID-19 complications. Methods:...
3.
Bae K, Shunmuganathan B, Zhang L, Lim A, Gupta R, Wang Y, et al.
NPJ Vaccines
. 2024 Feb;
9(1):43.
PMID: 38396073
The advent of SARS-CoV-2 variants with defined mutations that augment pathogenicity and/or increase immune evasiveness continues to stimulate global efforts to improve vaccine formulation and efficacy. The extraordinary advantages of...
4.
Ho V, Boon L, Cui J, Juequn Z, Shunmuganathan B, Gupta R, et al.
Aging Cell
. 2024 Feb;
23(4):e14099.
PMID: 38317404
Although the two-dose mRNA vaccination regime provides protection against SARS-CoV-2, older adults have been shown to exhibit poorer vaccination responses. In addition, the role of vaccine-induced T-cell responses is not...
5.
Gu Y, Shunmuganathan B, Qian X, Gupta R, Tan R, Kozma M, et al.
Sci Rep
. 2023 Dec;
13(1):21810.
PMID: 38071323
The scale and duration of neutralizing antibody responses targeting SARS-CoV-2 viral variants represents a critically important serological parameter that predicts protective immunity for COVID-19. In this study, we describe the...
6.
Tulsian N, Palur R, Qian X, Gu Y, DO Shunmuganathan B, Samsudin F, et al.
Nat Commun
. 2023 Nov;
14(1):6967.
PMID: 37907459
The changing landscape of SARS-CoV-2 Spike protein is linked to the emergence of variants, immune-escape and reduced efficacy of the existing repertoire of anti-viral antibodies. The functional activity of neutralizing...
7.
Murali T, Shunmuganathan B, Trueman E, Gupta R, Tan R, Sran H, et al.
Immunohorizons
. 2023 Oct;
7(10):708-717.
PMID: 37889158
COVID-19 vaccination has significantly impacted the global pandemic by reducing the severity of infection, lowering rates of hospitalization, and reducing morbidity/mortality in healthy individuals. However, the degree of vaccine-induced protection...
8.
Krishnananthasivam S, Li H, Bouzeyen R, Shunmuganathan B, Purushotorman K, Liao X, et al.
NPJ Vaccines
. 2023 Sep;
8(1):136.
PMID: 37749097
No abstract available.
9.
Krishnananthasivam S, Li H, Bouzeyen R, Shunmuganathan B, Purushotorman K, Liao X, et al.
NPJ Vaccines
. 2023 Aug;
8(1):127.
PMID: 37626082
Tuberculosis (TB) is an airborne disease caused by Mycobacterium tuberculosis (Mtb). Whilst a functional role for humoral immunity in Mtb protection remains poorly defined, previous studies have suggested that antibodies...
10.
Malisheni M, Chong C, Murali T, Purushotorman K, Qian X, Laiman A, et al.
Pathogens
. 2023 Jan;
12(1).
PMID: 36678399
Several human monoclonal Abs for treating Influenza have been evaluated in clinical trials with limited success despite demonstrating superiority in preclinical animal models including mice. To conduct efficacy studies in...